AR104856A1 - Derivados de difluorocetamida - Google Patents

Derivados de difluorocetamida

Info

Publication number
AR104856A1
AR104856A1 ARP160101323A ARP160101323A AR104856A1 AR 104856 A1 AR104856 A1 AR 104856A1 AR P160101323 A ARP160101323 A AR P160101323A AR P160101323 A ARP160101323 A AR P160101323A AR 104856 A1 AR104856 A1 AR 104856A1
Authority
AR
Argentina
Prior art keywords
substituted
heteroaryl
aryl
arylalkyl
cycloalkyl
Prior art date
Application number
ARP160101323A
Other languages
English (en)
Inventor
Mohr Peter
Reutlinger Michael
P Maerki Hans
A Kitas Eric
Iacone Roberto
Hornsperger Benoit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR104856A1 publication Critical patent/AR104856A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Reivindicación 1: Compuestos de fórmula (1) en donde: R¹ es alquilo, cicloalquilo sustituido, haloalquilo, heterocicloalquilalquilo sustituido, arilalquilo sustituido o heteroarilalquilo sustituido, en donde el cicloalquilo sustituido, heterocicloalquilalquilo sustituido, arilalquilo sustituido y heteroarilalquilo sustituido se sustituyen con R¹⁰, R¹¹ y R¹²; R², R³, R⁴, R⁶, R⁷ y R⁹ se seleccionan independientemente entre H, alquilo y cicloalquilo; R⁵ es arilo sustituido, arilalquilo sustituido, heteroarilo sustituido o heteroarilalquilo sustituido, en donde el arilo sustituido, arilalquilo sustituido, heteroarilo sustituido y heteroarilalquilo sustituido se sustituyen con R¹³, R¹⁴ y R¹⁵; R⁸ es adamantilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, dicicloalquilalquilo sustituido, arilo sustituido, arilalquilo sustituido, arilalquenilo sustituido, diarilalquilo sustituido, ariloxialquilo sustituido, diariloxialquilo sustituido, arilariloxialquilo sustituido, heteroarilariloxialquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, heteroarilalquenilo sustituido, arilheteroarilalquilo sustituido, arilheteroariloxialquilo sustituido o ariloxiheteroarilalquilo sustituido, en donde el adamantilalquilo sustituido, cicloalquilo sustituido, cicloalquilalquilo sustituido, dicicloalquilalquilo sustituido, arilo sustituido, arilalquilo sustituido, arilalquenilo sustituido, diarilalquilo sustituido, ariloxialquilo sustituido, diariloxialquilo sustituido, arilariloxialquilo sustituido, heteroarilariloxialquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, heteroarilalquenilo sustituido, arilheteroarilalquilo sustituido, arilheteroariloxialquilo sustituido y ariloxiheteroarilalquilo sustituido se sustituyen con R¹⁶, R¹⁷ y R¹⁸; R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷ y R¹⁸ se seleccionan independientemente entre H, halógeno, alquilo, haloalquilo, cicloalquilo, ciano, hidroxilo, alcoxi, haloalcoxi y fenilo; o sales farmacéuticamente aceptables.
ARP160101323A 2015-05-11 2016-05-09 Derivados de difluorocetamida AR104856A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15167151 2015-05-11

Publications (1)

Publication Number Publication Date
AR104856A1 true AR104856A1 (es) 2017-08-23

Family

ID=53174868

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101323A AR104856A1 (es) 2015-05-11 2016-05-09 Derivados de difluorocetamida

Country Status (8)

Country Link
US (1) US10428108B2 (es)
EP (1) EP3294718B1 (es)
JP (1) JP6757336B2 (es)
CN (1) CN107531653B (es)
AR (1) AR104856A1 (es)
HK (1) HK1245258A1 (es)
TW (1) TW201713613A (es)
WO (1) WO2016180751A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507176A (ja) 2016-03-04 2019-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｔｒａ１阻害剤としての新規ジフルオロケタミド誘導体
CN108699106B (zh) 2016-03-04 2021-11-30 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
SG11201810854SA (en) * 2016-06-21 2019-01-30 Orion Ophthalmology LLC Aliphatic prolinamide derivatives
CN114685453A (zh) * 2016-06-21 2022-07-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
JP2019522673A (ja) * 2016-07-18 2019-08-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｔｒａ１阻害剤としての新規なジフルオロケトアミド誘導体
JP2019526563A (ja) 2016-08-23 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｔｒａ１阻害剤としての新規ジフルオロケタミド誘導体
EP3504197B1 (en) 2016-08-23 2021-11-17 F. Hoffmann-La Roche AG New trifluoromethylpropanamide derivatives as htra1 inhibitors
CN116375794A (zh) * 2021-09-09 2023-07-04 广东众生睿创生物科技有限公司 酮酰胺衍生物及其应用

Also Published As

Publication number Publication date
CN107531653A (zh) 2018-01-02
JP6757336B2 (ja) 2020-09-16
HK1245258A1 (zh) 2018-08-24
US20180057526A1 (en) 2018-03-01
WO2016180751A1 (en) 2016-11-17
US10428108B2 (en) 2019-10-01
EP3294718A1 (en) 2018-03-21
CN107531653B (zh) 2021-10-19
JP2018516892A (ja) 2018-06-28
EP3294718B1 (en) 2020-04-29
TW201713613A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
AR104856A1 (es) Derivados de difluorocetamida
AR088293A1 (es) Inhibidores de proteina cinasa
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR099824A1 (es) Compuestos bicíclicos
AR096450A1 (es) Compuestos para la modulación de quinasas, y sus indicaciones
AR112682A1 (es) Compuestos herbicidas
AR103093A1 (es) Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR092742A1 (es) Piridinonas antifibroticas
AR089051A1 (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR092347A1 (es) Derivados de azaindol
AR103265A1 (es) Compuestos de azolina sustituidos con un sistema de anillos condensado
AR080332A1 (es) DERIVADOS DE CETOBENZOFURANO, PROCEDIMIENTO PARA SU SíNTESIS E INTERMEDIARIOS DE LA MISMA
CR20160578A (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona
AR109776A1 (es) Compuestos de p2x₃ y/o p2x₂/₃ y métodos
AR096423A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
AR095136A1 (es) Derivados de pirazol microbiocidas
AR101479A1 (es) Derivados de 6-alquinil-piridina
AR099914A1 (es) Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR087771A1 (es) Moduladores de la pde10

Legal Events

Date Code Title Description
FB Suspension of granting procedure